Program
CB03-154
A development code. Also written as “Test drug CB03-154 5mg group”, “Test drug CB03-154 10mg group” and “Test drug CB03-154 20mg group”.
Its studies are mostly in Epilepsies, Partial · Amyotrophic Lateral Sclerosis, led by Shanghai Zhimeng Biopharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Zhimeng Biopharma | 53 open or running | phase 3since Jul 11, 2025 | Aug 8, 2022 | Sep 2027phase 2 · NCT06612775 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2022First studies: 2 phase 1 studies in Healthy VolunteersFirst studyNCT05499260, NCT05502549
- Sep 19, 2024Phase 2 study in Epilepsies, PartialNCT06612775 · 180 planned · Australia
- Jul 11, 2025Phase 3 study in Amyotrophic Lateral SclerosisNCT07082192 · 240 planned · China
- Nov 16, 2025Phase 2 study in Epilepsies, PartialNCT07238868 · 144 planned · Australia
Ahead
- Sep 2027Primary completion: phase 2 study in Epilepsies, PartialNCT06612775
- Sep 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07082192
- Jan 2029Primary completion: phase 2 study in Epilepsies, PartialNCT07238868
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07238868Epilepsies, Partial · Australia | 2 | Recruiting | Jan 2029 | 144 |
| NCT07082192Amyotrophic Lateral Sclerosis · China | 3 | Recruiting | Sep 30, 2027 | 240 |
| NCT06612775Epilepsies, Partial · Australia | 2 | Recruiting | Sep 2027 | 180 |
| NCT05502549Healthy Volunteers · Australia | 1 | Completed | Nov 9, 2023 | 56 |
| NCT05499260Healthy Volunteers · United States | 1 | UNKNOWN | Mar 2, 2023 | 70 |
How it is read
Names in the registry
- “CB03-154”, 3 entries
- “Test drug CB03-154 5mg group”, 2 entries
- “Test drug CB03-154 10mg group”, 2 entries
- “Test drug CB03-154 20mg group”, 1 entry
- “Test drug CB03-154 15mg group”, 1 entry
Codes read as this program: CB03154.
Conditions, from the studies’ own filings
- Epilepsies, Partial, 2 studies
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.